SynthesisFrontiers in pharmacology2022
Linezolid resistance in multidrug-resistant mycobacterium tuberculosis: A systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Membrane Interfacial Organization Determines the Functional Performance of Liposomal Linezolid.Pharmaceutics · 2026Article
- Adverse effects of linezolid in the treatment of drug-resistant tuberculosis: a scoping review.Breathe (Sheffield, England) · 2026Review
- Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-ResistantPathogens (Basel, Switzerland) · 2026Article
- Acquired linezolid resistance in DR-TB: genotype-phenotype discordance and molecular heterogeneity in a retrospective cohort.BMC infectious diseases · 2026Article
- A Frameshift Mutation in the MethyltransferaseComputational and structural biotechnology journal · 2026Article
- Combating Drug-Resistant Tuberculosis: Advancements in Diagnostics and Therapeutics.Pulmonary medicine · 2026Review
- The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infectious diseases and therapy · 2026Review
- Wild-type MIC distribution and evaluation of epidemiological cut-offs of second-line TB-drugs in susceptible and MDR-TB clinical isolates from Chennai, India.Frontiers in microbiology · 2026Article
- Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.Antimicrobial agents and chemotherapy · 2025Article
- Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran.BMC microbiology · 2025Article
- Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.The Journal of infectious diseases · 2025Article
- Identification of novelFuture medicinal chemistry · 2025Article
- Cost-effectiveness of targeted next-generation sequencing (tNGS) for detection of tuberculosis drug resistance in India, South Africa and Georgia: a modeling analysis.EClinicalMedicine · 2025Article
- ThePeerJ · 2025Review
- Drug-resistant tuberculosis: a persistent global health concern.Nature reviews. Microbiology · 2024Review
- EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.Georgian medical news · 2024Article
- Relapse after treatment with standardized all-oral short regimens for rifampicin-resistant tuberculosis (RR-TB): A systematic review andJournal of clinical tuberculosis and other mycobacterial diseases · 2024Review
- Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients: Clinical Factors and Hematological Toxicities.Infection and drug resistance · 2024Article
- Linezolid resistance in patients with drug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Mechanisms of Linezolid Resistance in Mycobacteria.Pharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.